ARTICLE | Clinical News
EPI-2010: Began Phase I study
November 6, 2000 8:00 AM UTC
EpiGenesis Pharmaceuticals Inc., Cranbury, N.J. Product: EPI-2010 Business: Autoimmune/Inflammation Therapeutic category: Antisense Target: Adenosine A1 receptor mRNA Description: Inhaled antisense o...